Northwell Health appointed David J. Chung, a prominent oncologist-investigator, as director of clinical research at the Northwell Health Cancer Institute. In this newly created role, Chung also will serve as system chief of multiple myeloma across Northwell’s cancer centers.
Longer follow-up results from the investigational phase Ib/II OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
